Randomised controlled trial of vitamin D supplementation in sarcoidosis
Mark J Bolland, Margaret L Wilsher, Andrew Grey, Anne M Horne, Sheryl Fenwick, Greg D Gamble, Ian R Reid, Mark J Bolland, Margaret L Wilsher, Andrew Grey, Anne M Horne, Sheryl Fenwick, Greg D Gamble, Ian R Reid
Abstract
Objectives: The role vitamin D intake/production plays in sarcoidosis-associated hypercalcaemia is uncertain. However, authoritative reviews have recommended avoiding sunlight exposure and vitamin D supplements, which might lead to adverse skeletal outcomes from vitamin D insufficiency. We investigated the effects of vitamin D supplementation on surrogate measures of skeletal health in patients with sarcoidosis and vitamin D insufficiency.
Design: Randomised, placebo-controlled trial.
Setting: Clinical research centre.
Participants: 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D (25OHD) <50 nmol/L.
Intervention: 50 000 IU weekly cholecalciferol for 4 weeks, then 50 000 IU monthly for 11 months or placebo.
Primary and secondary outcome measures: The primary endpoint was the change in serum calcium over 12 months, and secondary endpoints included measurements of calcitropic hormones, bone turnover markers and bone mineral density (BMD).
Results: The mean age of participants was 57 years and 70% were women. The mean (SD) screening 25OHD was 35 (12) and 38 (9) nmol/L in the treatment and control groups, respectively. Vitamin D supplementation increased 25OHD to 94 nmol/L after 4 weeks, 84 nmol/L at 6 months and 78 nmol/L at 12 months, while levels remained stable in the control group. 1,25-Dihydroxy vitamin D levels were significantly different between the groups at 4 weeks, but not at 6 or 12 months. There were no between-groups differences in albumin-adjusted serum calcium, 24 h urine calcium, markers of bone turnover, parathyroid hormone or BMD over the trial. One participant developed significant hypercalcaemia after 6 weeks (total cholecalciferol dose 250 000 IU).
Conclusions: In patients with sarcoidosis and 25OHD <50 nmol/L, vitamin D supplements did not alter average serum calcium or urine calcium, but had no benefit on surrogate markers of skeletal health and caused one case of significant hypercalcaemia.
Trial registration: This trial is registered at the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au). The registration number is ACTRN12607000364471, date of registration 5/7/2007.
Keywords: THORACIC MEDICINE.
Figures
References
- James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976;278:321–34
- Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885–9
- Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. N Engl J Med 1986;315:755–7
- Bell NH, Gill JR, Jr, Bartter FC. On the abnormal calcium absorption in sarcoidosis. Evidence for increased sensitivity to vitamin D. Am J Med 1964;36:500–13
- Sandler LM, Winearls CG, Fraher LJ, et al. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q J Med 1984;53:165–80
- Sharma OP. Vitamin D, calcium and sarcoidosis. Chest 1996;109:535–9
- Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 1998;53:425–9
- Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 2000;39:707–13
- Bonnema SJ, Moller J, Marving J, et al. Sarcoidosis causes abnormal seasonal variation in 1,25-dihydroxy-cholecalciferol. J Intern Med 1996;239:393–8
- Taylor RL, Lynch HJ, Jr, Wysor WG., Jr Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. Am J Med 1963;34:221–7
- Alberts C, van den Berg H. Calcium metabolism in sarcoidosis. A follow-up study with respect to parathyroid hormone and vitamin D metabolites. Eur J Respir Dis 1986;68:186–94
- Larsson LG, Liljestrand A, Wahlund H. Treatment of sarcoidosis with calciferol. Acta Med Scand 1952;143:281–7
- Adler RA, Funkhouser HL, Petkov VI, et al. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003;325:1–6
- Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477–501
- Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 1991;8:29–34
- Rottoli P, Gonnelli S, Silitro S, et al. Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. Sarcoidosis 1993;10:161–2
- Hamada K, Nagai S, Tsutsumi T, et al. Bone mineral density and vitamin D in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:219–23
- Sipahi S, Tuzun S, Ozaras R, et al. Bone mineral density in women with sarcoidosis. J Bone Miner Metab 2004;22:48–52
- Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010;31:474–84
- Sharma OP. Vitamin D and sarcoidosis. Curr Opin Pulm Med 2010;16:487–8
- Sage RJ, Rao DS, Burke RR, et al. Preventing vitamin D toxicity in patients with sarcoidosis. J Am Acad Dermatol 2011;64:795–6
- Sweiss NJ, Lower EE, Korsten P, et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2011;13:265–72
- Angus RM, Sambrook PN, Pocock NA, et al. A simple method for assessing calcium intake in Caucasian women. J Am Diet Assoc 1989;89:209–14
- Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: 266–81
- Sattar N, Welsh P, Panarelli M, et al. Increasing requests for vitamin D measurement: costly, confusing, and without credibility. Lancet 2012;379:95–6
- Bolland MJ, Grey A, Davidson JS, et al. Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?. N Z Med J 2012;125:83–91
- Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010;340:b5664.
- Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:2997–3006
- Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009;2:CD000227.
- Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931–42
- Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. preventive services task force. Ann Intern Med 2011;155:827–38
- Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem 2009;55:1300–2
Source: PubMed